Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
1 hedge funds and large institutions have $3.83K invested in Amplify Treatments, Testing and Advancements ETF in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 10 closing their positions.
91% less funds holding
Funds holding: 11 → 1 (-10)
100% less capital invested
Capital invested by funds: $1.43M → $3.83K (-$1.42M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 10
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$850K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$515K |
| 3 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$27.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8.87K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
1
IFP Advisors
Tampa,
Florida
| $3.83K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$850K | -46,695 | Closed |
|
|
3
Citadel Advisors
Miami,
Florida
| – | -$515K | -28,290 | Closed |
|
|
FDCDDQ
4
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$27.3K | -1,500 | Closed |
|
|
5
UBS Group
Zurich,
Switzerland
| – | -$8.87K | -487 | Closed |
|
|
6
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$6K | -300 | Closed |
|
7
Osaic Holdings
Scottsdale,
Arizona
| – | -$5.08K | -277 | Closed |
|
|
CHC
8
City Holding Co
Charleston,
West Virginia
| – | -$4.28K | -235 | Closed |
|
|
TAM
9
Tucker Asset Management
Littleton,
Colorado
| – | -$4.21K | -231 | Closed |
|
|
SPIA
10
Steward Partners Investment Advisory
New York
| – | -$2.91K | -160 | Closed |
|
|
PCMC
11
Planning Capital Management Corporation
Paoli,
Pennsylvania
| – | -$19 | -1 | Closed |
|
GERM Hedge Fund Activity: Q3 2024 in Review
1 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q3 2024, worth a combined $3.83K — down 100% from $1.43M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GERM and 0 opened new positions — a net loss of 10 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, exiting entirely with an estimated $850K sold.
- 1 institutional investor held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q3 2024, down from 11 in Q2 2024.
- Funds reported $3.83K of Amplify Treatments, Testing and Advancements ETF stock for Q3 2024, down 100% quarter-over-quarter.
- 0 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q3 2024 and 10 closed out, a net change of -10 holders.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q3 2024 was Susquehanna International Group, an estimated $850K sold.
Based on aggregated 13F filings for Q3 2024.